Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Elritercept (KER-050) in Lower-Risk MDS and CMML
NCT04419649Phase 2Recruiting
- Sponsor
- Takeda
- Start
- Aug 2020
- Primary completion
- Oct 2029
- Modality
- Fc-Fusion Proteins
- Countries
- 8
01
Overview
A Phase 2 trial of elritercept in myelodysplastic syndrome (MDS), chronic myelomonocytic leukemia (CMML), anemia, sponsored by Takeda. Started Aug 2020; status: recruiting.
02
Drugs
elritercept
03
Conditions
myelodysplastic syndrome (MDS)chronic myelomonocytic leukemia (CMML)anemia
Beyond the preview
Go deeper on NCT04419649.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04419649.